Design Therapeutics (DSGN) Competitors $5.62 +0.05 (+0.90%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DSGN vs. VYGR, ATAI, SGMO, EDIT, BNR, ARDX, ANIP, CALT, ARQT, and MESOShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Voyager Therapeutics (VYGR), Atai Life Sciences (ATAI), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Burning Rock Biotech (BNR), Ardelyx (ARDX), ANI Pharmaceuticals (ANIP), Calliditas Therapeutics AB (publ) (CALT), Arcutis Biotherapeutics (ARQT), and Mesoblast (MESO). Design Therapeutics vs. Voyager Therapeutics Atai Life Sciences Sangamo Therapeutics Editas Medicine Burning Rock Biotech Ardelyx ANI Pharmaceuticals Calliditas Therapeutics AB (publ) Arcutis Biotherapeutics Mesoblast Design Therapeutics (NASDAQ:DSGN) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Does the MarketBeat Community believe in DSGN or VYGR? Voyager Therapeutics received 380 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 67.59% of users gave Voyager Therapeutics an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Voyager TherapeuticsOutperform Votes39067.59% Underperform Votes18732.41% Do insiders and institutionals believe in DSGN or VYGR? 56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 4.5% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is DSGN or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Design Therapeutics' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -18.01% -17.38% Voyager Therapeutics 15.80%8.33%6.15% Which has more volatility and risk, DSGN or VYGR? Design Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Does the media refer more to DSGN or VYGR? In the previous week, Voyager Therapeutics had 17 more articles in the media than Design Therapeutics. MarketBeat recorded 17 mentions for Voyager Therapeutics and 0 mentions for Design Therapeutics. Voyager Therapeutics' average media sentiment score of 0.14 beat Design Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Design Therapeutics Neutral Voyager Therapeutics Neutral Which has higher valuation and earnings, DSGN or VYGR? Voyager Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$66.86M-$0.85-6.61Voyager Therapeutics$163.78M1.89$132.33M$0.717.96 Do analysts rate DSGN or VYGR? Design Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 24.56%. Voyager Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 200.62%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Voyager Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryVoyager Therapeutics beats Design Therapeutics on 15 of the 18 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$318.20M$6.64B$5.21B$8.83BDividend YieldN/A8.11%5.07%4.09%P/E Ratio-6.6110.66113.2217.54Price / SalesN/A389.981,251.41162.39Price / CashN/A52.5939.9036.29Price / Book1.2610.367.066.49Net Income-$66.86M$153.36M$118.87M$225.61M7 Day Performance-3.10%4.62%2.20%3.59%1 Month Performance-0.88%-7.68%-3.08%3.43%1 Year Performance154.30%33.33%33.58%29.15% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.6632 of 5 stars$5.62+0.9%$7.00+24.6%+154.3%$318.20MN/A-6.6140VYGRVoyager Therapeutics4.6684 of 5 stars$5.66+4.2%$17.00+200.6%-17.8%$308.91M$163.78M7.97100ATAIAtai Life Sciences2.6057 of 5 stars$1.61+5.9%$9.00+459.0%+47.7%$270.16M$331,000.00-1.8783Analyst RevisionSGMOSangamo Therapeutics2.16 of 5 stars$1.88-4.1%$7.00+272.3%+424.7%$392.26M$176.23M-2.51480EDITEditas Medicine4.7036 of 5 stars$2.44+3.0%$9.08+272.3%-76.7%$201.42M$61.76M-0.93230Analyst RevisionBNRBurning Rock BiotechN/A$5.60+4.1%N/A-37.8%$57.34M$75.70M-1.121,390Gap UpARDXArdelyx4.016 of 5 stars$5.31+3.7%$10.42+96.2%+23.2%$1.26B$251.85M-17.15267Insider TradeANIPANI Pharmaceuticals4.2863 of 5 stars$56.91+1.9%$77.33+35.9%+10.1%$1.20B$486.82M-103.07642Positive NewsCALTCalliditas Therapeutics AB (publ)0.2735 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsARQTArcutis Biotherapeutics1.7743 of 5 stars$10.14-1.0%$15.50+52.9%+439.4%$1.19B$59.61M-5.68150MESOMesoblast1.2372 of 5 stars$10.11-0.7%$11.50+13.7%+277.2%$1.15B$5.90M0.0080Gap Down Related Companies and Tools Related Companies VYGR Alternatives ATAI Alternatives SGMO Alternatives EDIT Alternatives BNR Alternatives ARDX Alternatives ANIP Alternatives CALT Alternatives ARQT Alternatives MESO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DSGN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSGN Stock Alerts